Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Gjettum – page 30

616 clinical trials in Gjettum, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Gjettum at a glance
616
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

616 trials in Gjettum

Open in trial search

Study on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of Olezarsen (ISIS 678354) in Patients with Severe Hypertriglyceridemia: Testing Effects on Triglyceride Levels

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Schizophrenia

Not recruiting

Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Iclepertin
  • Sponsor:Boehringer Ingelheim International GmbH

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Hypertriglyceridaemia+1

Not recruiting

Study of Olezarsen (ISIS 678354) for Patients with High Triglycerides and Heart Disease or Severe High Triglycerides

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Gjettum

What the registry says about research in the country

01 Gastroenterology Research

Innovative trials focusing on inflammatory bowel diseases, including studies of combination therapies for both Crohn's Disease and Ulcerative Colitis. Research aims to evaluate new treatment approaches using targeted biological agents.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Combination Therapy Assessment

These studies explore dual-therapy approaches to improve clinical outcomes for patients with moderate to severe disease activity.

02 Cardiovascular Studies

Research focusing on prevention and treatment of stroke and cardiac conditions, including innovative approaches for managing atrial fibrillation and evaluating new anticoagulation therapies.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Thrombolysis Research

Trials aim to improve outcomes in acute ischemic stroke and prevent cardiac complications.

03 Musculoskeletal Medicine

Comprehensive research into orthopedic conditions, including studies on osteoarthritis, carpal tunnel syndrome, and hip fracture treatments.

  • Joint Disease Management
  • Surgical vs. Conservative Treatment
  • Post-fracture Care

Investigations compare different treatment approaches and timing of interventions for optimal patient outcomes.

04 Infectious Disease Research

Studies addressing various infectious conditions including COVID-19 and mpox, evaluating novel therapeutic approaches and treatment strategies.

  • COVID-19 Treatment Trials
  • Mpox Management
  • Antiviral Therapy Assessment

Research focuses on understanding disease progression and testing new therapeutic interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.